(Q34227026)

31 July 2017

1 reference

title

Apheresis for lupus erythematosus: state of the art. (English)

1 reference

31 July 2017

1 reference

D J Wallace

1

1 reference

31 July 2017

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

10

1 reference

31 July 2017

3

1 reference

31 July 2017

193-196

1 reference

Plasmapheresis in the management of acute systemic lupus erythematosus?

31 July 2017

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Apheresis for lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Apheresis enhances the selective removal of antinuclear antibodies in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Treatment of hemorrhagic lupus pneumonitis with plasmapheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Predictive value of clinical, laboratory, pathologic, and treatment variables in steroid/lmmunosuppressive resistant lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

Characteristics of responders and nonresponders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301671920760

10.1191/096120301671920760

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11315351